Trial Profile
Safety, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Dose of CNTO 3649 in Healthy Adult Men and Multiple Subcutaneous Doses of CNTO 3649 in Patients With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs CNTO 3649 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Janssen Pharmaceutical KK
- 27 Aug 2014 New trial record